 Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
| Descriptor ID |
D017430
|
| MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
|
| Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 3 | 0 | 3 | | 2003 | 2 | 4 | 6 | | 2004 | 0 | 3 | 3 | | 2005 | 2 | 2 | 4 | | 2006 | 3 | 2 | 5 | | 2007 | 1 | 4 | 5 | | 2008 | 2 | 4 | 6 | | 2009 | 3 | 4 | 7 | | 2010 | 2 | 1 | 3 | | 2011 | 4 | 2 | 6 | | 2012 | 4 | 6 | 10 | | 2013 | 1 | 3 | 4 | | 2014 | 1 | 7 | 8 | | 2015 | 3 | 5 | 8 | | 2016 | 6 | 3 | 9 | | 2017 | 0 | 3 | 3 | | 2018 | 1 | 5 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.
-
Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 11; 19(11):1504-1515.
-
Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther. 2018 12; 17(4):1103-1108.
-
Robin TP, Maroni PD, Chin BB, La Rosa FG, Bernard B, Pugh TJ. Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy Intensification. Oncology (Williston Park). 2018 07 15; 32(7):360-3, 369, CV3.
-
Scherer LD, Kullgren JT, Caverly T, Scherer AM, Shaffer VA, Fagerlin A, Zikmund-Fisher BJ. Medical Maximizing-Minimizing Preferences Predict Responses to Information about Prostate-Specific Antigen Screening. Med Decis Making. 2018 08; 38(6):708-718.
-
da Silva RD, Kim FJ. Prostate Cancer - Local Treatment after Radiorecurrence: Salvage Cryoablation. Int Braz J Urol. 2018 May-Jun; 44(3):435-439.
-
Ryan CJ, Crawford ED, Shore ND, Underwood W, Taplin ME, Londhe A, Francis PSJ, Phillips J, McGowan T, Kantoff PW. The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. J Urol. 2018 08; 200(2):344-352.
-
Maccini MA, Westfall NJ, Van Bokhoven A, Lucia MS, Poage W, Maroni PD, Wilson SS, Glodé LM, Arangua P, Newmark J, Steiner M, Werahera PN, Crawford ED. The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer. Prostate. 2018 05; 78(7):506-511.
-
Flaig TW, Plets M, Hussain MHA, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol. 2017 Nov 09; 3(11):e170231.
-
Frank SJ, Pugh TJ, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, Davis JW, Kim J, Choi H, Troncoso P, Kuban DA, Choi S, McGuire S, Hoffman KE, Chen HC, Wang X, Swanson DA. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):374-382.
-
Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M, Kwok Y, Dignam JJ, Sandler HM. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):296-303.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|